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Drug-induced photosensitivity refers to adverse 
cutaneous responses which follow the combined or 
s uccess ive exposure to certa in chemica ls (photo-
sens iti zers) and to light. Histori ca ll y, the term 
" drug" was quite appropriate, s ince exposure to 
t he che mica ls concerned was for their t herapeutic 
propert ies . However, as used at present, the term 
" drug photosens it ivity" in clud es adver e re-
sp onses to a broad group of agents, including 
drugs a nd chem ica ls used for such diverse pur-
poses as cos metics (1) , food preservatives (2) , 
chemicals used in the household (3), industry (4) 
and agricu lture (5). 
At present two distin ct mechanisms, photo-
toxic a nd photoa llergic, a re recognized which can 
mediate these reactions. In addi tion , drug photo-
sensitivity has been documented in at least three 
systemi c di seases : porphyria, lupus erythemato-
sus, and pellagra. Selected cases of each of these 
diseases have been shown to have been induced 
by drugs or mimicked by drug reactions. The pre-
cise role of drug photosens itivi ty in these diseases 
is presently not clearly understood (Table 1), and 
the pathogenet ic mechanisms discussed later in 
this paper therefore must be considered hypothet-
ical. 
Biophysical Aspects of Photo toxic and 
Photoallergic Drug Reactions 
Molecula r studies of the photosensit izing com-
pounds listed in Tables II and III indicate that 
these compounds have few chemica l features in 
common, except' that a ll a re relat ively sma ll, 
h a ving a molecula r weight of 500 gra ms or less 
per mole; a ll are resonati ng, many of t ri cyclic 
structure with fluorescent properties, and all ab-
sorb ultraviolet or vis ible light. It is the absorp-
tion of light by the drug (chemica l) that is crucia l 
for furnishing the energy which ini t iates a photo-
toxic or photoa llergic reaction ; ~herefore, it is 
obligatory that the chemica l be encountered by 
the host before exposure to the source of ene!'gy 
occurs. The energy source may emit natura l or 
artificial light . Exposure to different photosensi -
tizers may occur through contact, ingestion or 
injection. 
The principl es governing the biologic effects of 
ul t rav iolet and visible light rest heav ily upon pi-
oneer studies of Stark, Planck, Einstein , Grot-
thus, Draper, Bunsen and Roscoe, and have been 
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comprehensively reviewed by Giese (6) and Smith 
(7). Their application to drug photosens itivi ty 
reactions may be summarized as fo llows: Light is 
a hete rogeneous moiety consisting of numerous 
pa rticles, conta inin g discrete and different 
a mounts of energy ca ll ed quanta or photons. The 
totality of these particles is referred to as the 
electromagnet ic s pectrum. T hose particles 
reaching the earth 's surface a re schematica lly 
depicted in Figure 1. For qualitative analys is the 
actions of the particles can a lso be considered as 
waves of energy. Thus, energy associated with 
wavelengths from 400- 800 nm is capable of ex-
citing the ocula r photoreceptors and is referred to 
as visible light, whi le wavelengths in the 200 to 
400 nm range are invisibl e and com monly ·call ed 
ultrav iolet light. As only negligible solar rad iation 
lower tha n 290 nm reaches the earth 's surface, 
drug photosensitivity reactions usually are in -
duced by radiat ion in the 290 nm- 800 nm range. 
It is conce ivable that energy in the form of sti ll 
shorter wavelengths such as x- rays and gamma 
rays or of longer wavelengths in the form of in -
fra red and radio wave could a lso initiate drug 
photosensitivity reactions; however, to date no 
clinica l instances of such reactions have been re-
ported. There can be no drug photosensitivity 
reaction unless energy is first absorbed by the 
photo ensit izing agent (photosensiti zer or cluo-
mophore). In a ddi t ion, a photosensitizer wi ll only 
absorb a single photon in the course of any one 
photochemica l reaction . This action is further 
qualified by the fact that a given chemica l, be-
cause of its unique molecular structure, is capable 
of absorbing photons only of a specific wave-
length. This wavelength, as determined in vitro, 
i.e. in a spectrophotometer, is termed the absorp-
tion spectrum of a chemical. When an adverse 
react ion occurs in the skin , the wavelength 
causing t he un toward effect is determined in vivo 
wi th a monochromator or other light source with 
appropriate fi lters. This is referred to as the ac-
tion spectrum of a given reaction. Although the 
absorption spectrum and the action pectrum 
coi ncide quite freque nt ly, t here are instances 
where thi s does not obtain because the photosen-
siti zer has been a ltered metabolically or photo-
chemically in the course of the reaction . 
Another fundamental principle of physics that 
is applicable to drug photosensitivity reactions, is 
that there is a relationship between the concen-
tration of the photosensit izer, the dose of the ex-
cit ing radiation and the magnitude of the cuta-
neous response. 
The energy kinetics of the reactions which 
fo llow exposure of the photosensitizer to appro-
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priate wavelengths of light have been firmly es-
ta blished and are shown in Figure 2 (8). Afte r 
absorpt ion of a photon the photosensit izer leaves 
its normal ground state energy level and enters a 
new state of higher energy content, referred to as 
the exc ited state. In many cases this is the resul t 
of an electron moving to an outer shell a nd is 
called the exc ited singlet state. T he exc ited sta te 
of the photosensit izer is t ransient and unstable, 
with in terna l conve rs ion rapidly occurrin g. D iss i-
pation of the absorbed energy by the photosensi-
t izer and return to its ori gina l ground state can be 
accompli shed by numerous pathways, occurring 
either independentl y or concurrent ly. Common 
routes include fluorescence, t ri plet sta te, phos-
phorescence, heat, vibration, cha rge t ransfer, free 
radi cal formation a nd , in selected cases, chemica l 
alteration of the chromophore resul t ing in the 
format ion of a new compound . It is in the process 
TABLE I 
Biologic mechanisms of drug-induced photosensitivity 
Entity Mcchnnism Exn mplc 
' Drug phototoxicity E nergy t ra nsfer Psora len 
· Drug photoallergy De layed hypersen- Tetrachl oro-
sit ivity sa li cylana-
Drug-induced por- Enzyme induction I ide 
phyria 
Drug- induced lu pus 
erythematosus 
Drug- induced pe l-




Metabo li c de fect Isoni cot ini c 
of Coenzy mes I ac id hy-
a nd II draz ide 
TABLE II 












of t he d iss ipation of energy by the photosensit izer 
that ma ny of the adverse biologic effects occur (9) . 
Before exposure to light, photosensiti ze rs a re 
sa id to be at a ground or "satisfi ed" energy state. 
T hey normall y have an orbi ta l confi gura tion in 
whi ch two electrons in a given orbi t a re spinning 
in oppos ite directions, resulting in magnetic neu-
t ra li ty . When a photon is absorbed by the photo-
sensit ize r, one of the electrons is ejected to a 
higher unfilled orbi t resul t ing in an exc ited sin-
glet molecular state. In this exc ited singlet state 
the electron, which was ejected to a higher orbi t, 
may be spinning in a reversed direction. In this 
instance, it is magnet ica ll y unbalanced and ca lled 
a triplet state energy form . The triplet state thus 
represents an exc ited molecule tha t has an orbi tal 
electron with a n unpa ired spin . It is in the t riplet 
state that most photochemica l reactions of the 
phototox ic ty pe occur. The singlet exc ited state 
car a lso theoreti ca lly be an active component of 
photosensiti zation. However, it is relati vely short-
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F tG. 1. Average intensity of various wavelengths of solar energy reaching the earth 's surface. 




FIG. 2. Molecular energy levels concerned in photo-
chemi ca l processes (8). 
10- a sec. so that sin glet reactions probably are of 
negligible importa nce. Part A of Table III indi -
cates that most photosensiti zers, S 0 , when excited 
by an appropriate quantum of light hv, enter the 
excited singlet state, S ' , and then the t riplet 
state, S". Part B of Table III indicates that the 
tripl et state of the photosensit izer is trans ient, 
w ith subsequent energy t ransfer to a n adjacent 
substrate (B2) or to molecula r oxygen (B3). In 
both cases the exc ited substrate or oxygen will, on 
subsequen t react ions, lead to the formation of 
peroxides a nd photo-oxidation of substrate. A 
third mechanis m of probab le major biologic im-
portance (B4) is one in which the photosensitize r 
combines with substrate before irrad iation. After 
excitation this unit S 2RH 2 will av idly uni te with 
oxygen, forming perox ides and wi ll participate in 
ox idative processes. It is full y rea li zed that many 
of these reactions occur simultaneously a nd to 
different degrees with different photosensitizers. 
It is a lso, for theoretical purposes, assumed that 
the photosensiti zer returns to its ori gina l form 
a nd is not chemica lly a ltered. 
Phototox£c Drug Reactions 
Pioneer studies by Raab (10) in 1900, which 
dealt exclusively with the unice llular organism 
paramec ium, described photob iologic prin ciples 
which today a re still applicab le to many of the 
drug photosensitiv ity reactions seen in man. He 
noted that when paramecia were exposed to sun-
light alone, or were placed in an acridine so lu tion 
in the dark, no adverse reaction occurred . How-
ever, when the pa ramecia were in the ac ridine 
solu tion and then were exposed to light, a letha l 
reaction occurred. Irrad iation of the acridine dye, 
before it was added to the colony of paramecia, 
caused no adverse response. Raab a lso noted that 
the duration of exposure to sunlight, as we ll as 
the concentration of the dye in the so lut ion, were 
important factors in this reaction. In expanded 
studies oxygen was soon shown by Tappeiner to 
be a crucia l prerequisite for occurrence of the 
light-induced effect (ll). Because of the oxygen 
requirement, this phenomenon was referred to as 
a photodynamic reaction, in contrast to photo-
chem ica l reactions such as take place on x-ray 
fi lm. 
The principles noted by Raab, with minor qual-
ifi cations, also apply to photobiologic reactions in 
vira l (17), becterial (13) , fun gal (14), and mam-
ma lian systems (15). Under controlled conditions, 
100% of these organisms will exhibit a photosensi-
t ive response on the first exposure to drug and 
light. The term "phototoxic" was in t roduced by 
S. Epstein in 1939 to describe certa in experi -
menta l findings in patients who received intra-
dermal injections of sulfanilamide and exposure 
to ultraviolet light (16). The features of the photo-
toxic reaction to sulfa nilamide, which were also 
observed by Burkhardt (17), fulfilled all the phe-
nomena desc ribed by Raab in paramecia, except 
that oxygen requirement was not investigated in 
these reactions in man and consequently was also 
not considered in the defini t ion . Indeed, it is now 
well established that oxygen is not needed in the 
ph ototox ic reactions induced by certain drugs, 
e.g. psoralens (18). Phototoxic reactions in which 
an ob ligatory role of oxygen has been demon -
strated, are referred to as photodynamic. T here-
fore, while a ll photodynamic reactions are photo-
toxic, not a ll phototox ic reaction a re photody-
nam ic. 
The list of drugs with phototoxic properties in 
man has been steadily expanding in recent years 
(19) . Table II presents some of the more impor-
tant examples. 
During the past decade an increasing number 
of photobiologic studies have dealt wi th the basic 
question as to how light exposure converts a drug, 
that was ad ministered for therapeutic benefit, 
into an agent that becomes harmful to the pa -
tient. The major contribu tions to the so lu tion of 
this problem have been made on a subcellular 
level and can perhaps best be summarized using 
spec ific exa mples of phototoxic drugs effecting 
primary damage to selective sites on the nucleus, 
cytoplasmic organelles and ce ll membrane. 
Nuclear Ph.ototox£c Damage. Drug phototox-
icity associated with exposure to furocoumar in 
(psoralens) has been noted to produce letha l and 
mutagenic effects in bac teria (18, 20). E legant 
studies by M usajo et al. (21, 22) have been con-
ce rned with the in teraction of psoralens with nu-
cleic acids. They showed that a non-damaging 
chemi ca l co m plex formed when psora len was 
ad ded to a solut ion of DNA in the dark. However, 
when DNA so lu t ion was exposed to 365 nm rad ia-
tion in the presence of p ora len, this compound 
reacted with nucleic acids to form a C,-cyclo-ad-
dition product with the 5,6 double bond of the 
pyrimidine base of DNA (Fig. 3). T he reaction 
was spec ific for pyrimidines, as purine derivatives 
showed no photoreactivit.y with psoralen (23, 24). 
The reaction did not require oxygen . Additional 
studies by Cole (25) have demonstrated that psor-
alens may a lso form cross- linkages between the 
strands of DNA. T he spec ificity of psora len for 
DNA appea rs to be exceedingly high, but to a 
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FIG. 3. General type of psora len photoreaction wi th. 
pyrimidi ne base of DNA. A cycloaddition product is 
formed from the opening of the 5,6-double bond of 
thymine and the 4', 5' -double bond of psora len. 
lesser extent other phototox ic compounds, such as 
acridine orange, a lso have a chem ica l affini ty to 
locali ze in the nucleus of cells (26). 
Cytop lasmic Phototoxic Damage . Lysosomes 
have been studied in cons iderable deta il as th e 
prime sea t of dru g ph ototoxicity by Alli son , 
Magnus and Young (27). Studi es utili zing an thra-
cene and monkey kidney cell s demonstrated the 
loca li zation of anthracene primarily in the cyto-
plasmic lysosomes. Irrad iation with 360 nm en-
ergy resulted in the demonstrat ion of hi gh ac id 
phosphatase activ ity, whi le con tro l experim ents, 
carried out in the dark, showed no assayab le hy-
drolytic enzymes. 
Cell M embrane Phototoxic Damage. T he red 
blood cell has been se lected as a model to study 
phototoxic cell membrane damage because of its 
anuc lear structure and absence of cytoplas mic 
organe ll es. Certa in dyes such as rose benga l (27), 
which are known to concentrate pr ima ril y on the 
cell membrane, and num erous other phototox ic 
agents have been assayed us ing red blood ce lls. 
Adding hematoporphyrin or protoporphyrin to 
red blood cell s or using cell s from patients with 
erythropoietic protoporp hyr ia, i.e . ce ll s which 
contain excessive amounts of protoporphyrin, a 
unifying concept of the mechanism of photody-
namic cell membrane damage has been proposed 
by Hsu, Ha rber a nd Goldstein (28). T he mecha-
nism of damage (Figure 4) is one of colloid os-
motic he molys is mediated by perox ide formation 
fo llowing porphyri n exc itation (29) . T here have 
been few in uiuo studies on the subcellula r locali-
zation of the majority of phototoxic drugs a nd 
consequently the site of action of most remains 
unknown. In fact, many compounds probab ly 
have mu ltip le s ites of action. T he left portion of 
Figure 5 is offered as a working hypothesis indi -
cating that, re ga rdless of the s ite of action, suffi -
cient damage to either nuclear, cytoplas mic or 
cell membrane structures can cause cell death. 
Biologic and Environmental Factors Affec ting 
Phototoxic Responses. Although in vitro studi es 
offer a fair degree of accuracy in predicting poten-
tially phototoxic agents in man, studies in other 
models have proved more reliab le. T hese have 
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included fun gi (14), mice (30) , red blood ce ll s (31), 
and gui nea pigs (32). However, of paramount s ig-
nifica nce in discussing phototoxic drug reactions 
rema ins the question as to what happe ns to man 
w hen he encounters the combination of drug a nd 
s unlight under physiologic environmenta l condi -
tions. T heoreti ca lly, one would pred ict t hat, if a 
s uffi cien t a moun t of li ght a nd a suffi cien t ly high 
concent ra tion of drug were present, 100% of the 
population would react adversely on firs t ex po-
sure . T he fac tors tha t make the incidence of pho-
totoxic reactions so varia ble in actua l practice, 
are onl y partially und e rstood . Howeve r, t he 
known va ria bles include t he fo llowin g: 
Topica l exposure. Abso rpt ion into the s kin is 
obvious ly required before a che mi ca l can act as a 
photosensiti zing agen t . Porphyrins, for exam ple, 
applied topica lly to the skin evoke no adverse 
reaction in t he presence of the activating wave-
lengths of li ght (33). Absorp t ion at differen t skin 
sites is stron gly influenced by a variety of loca l 
facto rs such as the thi ckn ess of the s tratum cor-
neum a nd th e tota l surface a rea of adn exa l 
gla nds. T he a mount a nd loca li zation of mela ni n 
present in t he epide rmis have a lso been shown to 
stron gly influe nce t he phototox ic res ponse to 
agents such as ta r (4) and psora len (5), wit h ne-
groes be ing a fforded considerab le p rotection as 
compared to caucasians. Chemica l a lte ration of 
phototox ic agents by bacte ria l a nd host enzy me 
systems has not been extensively studied , but 
could a lso be of import in the phototox ic potent ia l 
of a dru g. As with other a<7ents, in creased tem-
perature (34) a nd relat ive humidity (35) a re asso-
ciated with a greater phototoxic response , pre-
s umably through fa cili tat ion of abso rpti on in to 
the skin . 
Syste mic exposure. Depend ing on the route of 
syste mi c administrat ion, t he photosensitiz ing ef-
fect will be in!luenced by num erous factors, in -
cluding the rate of abso rption , metabolis m, and 
excreti on. Pe rs istence of t he drug and its concen-
tration in the skin after systemic ad ministration 
perhaps a re the mos t crucial fac tors. Re la tive ly 
few stud ies ha ve been published regarding cuta -
n eo us ce llula r m eta bo li s m of photose ns it izing 
drugs. 
Photoa llergic Drug Reactions 
Durin g t he past decade adva nces in photo-
ch emist ry a nd immunology have made this entity 
readi ly unders tandable in terms of a spec ific type 
of immunologic reaction. The term drug photoa l-
lergy at this t ime a pplies only to cell -mediated 
delayed immunologic res ponses, s ince these a re 
the only ones which have been adequate ly investi-
gated . However, it can be ant icipated that other 
for ms of immunologic responses, such as reactions 
med iated by lgE s kin -sensit izing an tibodies, in 
the future may we ll be observed . The ce ll -medi -
ated a ll e rgic res ponses due to drugs plus li ght are 
effected by the reticu loendothelia l system and in 
all respects appear identica l to cellular mecha-
ni s ms mediat in g con tact hypersens itivity, not 
involving li gh t, due to simple chem ica ls such as 
d ini troc hl orobenze n e (DNCB) and poi so n ivy . 
T he role of li ght relates so lely to a photochemical 
reaction which a lte rs the haptenic group or the 
avidi ty with which the ha ptenic group combines 
with carri er prote in to form a complete photoan -
t igen . Ana lysis of the chemica l agen ts listed in 
Table IV indicates that, s imila r to phototoxic 
compounds, photoa llergeni c compounds are res-
onating structures that absorb ul traviolet light 
a nd have a molecular weight of approx imately 
500 gms per mole or less; many of t hem !luoresce. 
Indeed , us ing an appropriate in vitro or in vivo 
model (36, 30, 37) , a ll compounds associated with 
photoa ll ergic reactions which have been so tested 
wi ll , in suffi ciently high concentrations, eli cit a 
phototox ic res ponse. T he converse is not true, as 
most of the dyes a nd other compounds such as 
anthracene and porphyrins, whi ch may be asso-
ciated wi t h phototox ic responses, clinica lly have 
not been shown to be photoa ll ergeni c. For reasons 
t hat are not under tood at t his t ime, a ll photoal -
lergic reactions have a n action spectrum above 
3.1 5 nm, while those of phototoxic agen ts closely 
correspond to the absorpt ion spectrum of the 
compou nd and may occur at lower wavelengths. 
Table V indicates these a nd other sa lient cl inica l 
a nd laboratory d ifferences between phototoxic 
a nd photoa ll ergic react ions. T he biophysical and 
TABLE lV 
Major groups of photoollergen.ic agents in man 
Antibacterial co mpounds 
Halogenated sa licy lani lides and related com-
pounds . 













Ora l hypoglycemic age nts 
a) Tolbut amide (o ri nase) 
b) Chlorpropa mide (diabinese) 
unsc reens 
Substituted benzoic acids 
Tranqui li zers 
a) Chlorpromazine (thorazine) 
b) Chlord iazepoxide (librium) 
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chemical pathways following exc itat ion of a mole-
cu le can, in both phototox ic and photoallergic 
reactions, resu lt in ce ll destruction as shown in 
F igure 5. However, t here is no immunologic rec-
ogni t ion by t he host in phototoxic react ion , 
whereas production of immunocom peten t cells by 
t he host is crucial fo r the occurrence of photoal -
lergic reactions. The remai ning commen ts in thi s 
section concerning drug photoallergy deal with 
the nature of the photochemical a lteration of the 
drug, the experimental ev idence that the photo-
sensitivity indeed is an immunologic reaction a nd 
t he relationship of drug photoall ergy to the entity 
of pers istent li ght reactors described by Jill son 
(38). 
TABLE V 
Characterist ics of drug induced photosensit ivity* 
Reaction 
Reaction possib le on Yes 
first exposure 
Incubation peri od No 
necessary after first 
exposure 
Chemi ca l alteration of No 
photosensitizer 
Covalent bind ing with No 
Phot.ot.ox ic 
carrier 
Clinical changes Usually like 
sunburn 
" Flares" at distant No 
previously in volved 
sites possible 
Can persistent li ght No 
reaction develop 
Cross- reactions to Infrequent 
stru ctura lly re lated 
agents 
B roa<:lenin g of cross - No 
reactions foll owing 
repeated photo-
patch testing 





Usua ll y rela-
t ive ly hi gh 
(theoretically 
100%) 
Usua lly similar 
to absorption 
spectrum 
Passive transfer No 
Lymphocyte stimu la- No 
tion test 
Macrophage migration No 
inhibition test 













Usua lly very 
low (but the-
oretica ll y 
could reach 
100%) 
Usua lly hi gher 
wave length 






Concept of Photoallergy. Developments in pho-
toa llergy derived a t remendous impetus from the 
fundamental conce pts developed by Stepha n 
Epstein in 1939 (16). At this time he proposed t he 
existence of two major pathways by which the 
photosens iti zing effect ca n occur. One of these 
was photoallergy, which involved an immunologic 
mechanism, whil e the other, phototoxicity, was 
noniromunologic. Epstein showed, and Burck-
hardt (17) soon confirmed, that it is possible to 
induce specifica lly a ltered a lle rgic reactivity to 
the combined effects of sulfanila mide and light in 
subjects in whom sulfanilamide a lone and light 
alone produce no detectable reaction . S ince Ep-
ste in 's original obse rvations, many clini ca l exa m-
pl es of photoa llergic sens iti zation have been re-
ported (39) . Among these, photoalle rgic contact 
sensit ization has been subjected to the most de-
ta iled studies. 
Experimental Induction. Knowledge of photoal -
lergy was great ly advanced by the induction of 
experimenta l photoallergic contact dermat itis in 
guinea pigs . Th is was first reported by Schwarz 
and Schwarz (40) in 1957 with sulfa nilam ide. 
Vinson et al. (41) induced contact photoallergy 
with tetrachl orsali cy lanilide (TCSA) a nd we h ave 
induced contact photoall e rgy with TCSA as well 
as with tribromosa li cylanilide (TBS) and other 
related compounds (42). More recently Schwarz 
(43) has experimenta lly induced contact photoal-
lergy to chlorpromazine. It is noteworthy t hat in 
most of these expe riments the induction of pho-
toallergy, in con t rast to e licitation , required not 
on ly the action spectrum long wavelen gth ultravi-
olet radiat ion , but a lso erythrogenic 280- 320 nro 
radiation. 
In 1968 Willis and K ligman (44) reported the 
experimenta l induction of photoall ergic contact 
· sens itization to halogenated sali cyla nilides and 
related chemica ls in human volun teers. Their 
procedure for induction of contact photoallergy 
a lso included the administra t ion of erythrogen ic 
radiation, but for eli citation in the a lready sensi-
t ized volunteers only non-erythrogenic radiation 
was used. 
From the experimenta l results in guinea pigs 
a nd in man one can conclude that, in consonance 
with what occurs clinically in ma n, one some-
times induces contact photoallergy a lone; at other 
t imes one induces contact a lle rgy a lone, a nd at 
still other t imes one induces both contact pho-
toa llergy and contact allergy. 
Hapten -carrier Protein Binding. Biochemical 
determination of hapten-carrier protein binding 
s ites has not yet been done for eithe r photocon-
tact a llergens or contact a llergens with the pos-
sible exception of DNCB (45) . We have specu -
lated in previous publications (46), on the basis of 
studies by Coxon, Jenkins and Welti (47) , that in 
TCSA photoa llergy the complete photoantigen is 
formed by a covalent uni on of the car rier protein 
with the ava ilab le si te a t the 3 carbon position of 
the benzoic ac id nucleus of the ha logenated sali-
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cylani lid e (Fig. 6f This hypothes is seems attrac-
tive as a highly reactive free radical site in this 
position has been demonstraterl to occur fo llowing 
the homolytic cleavage of the carbon-ha logen 
bond after exc itation with 360 nm radiation (47). 
In contrast one would postu late that, in the 
absence of light, t he most li kely union between 
the halogenated sa li cy lani lide and the ca rri er pro-
tein wou ld occur at the OH group on the 2 carbon 
or, less likely, at the carbonyl group bridging the 
two aromatic rings. The difference is diagramati -
cally illustrated in Figure 7. 
Passive Transfer. While photoallergic contact 
dermatitis clinically has shown all the attributes 
of an all ergic sensiti zation, and despite the exper-
imental induction of photoallergy in man and in 
guinea pigs, it was necessary to obtain immuno-
logic proof for an a ll ergic mechanism as well. Our 
group was ab le to demonstrate successfully the 
pass ive transfer of contact photoallergy from ac-
tively sensitized to non-sensiti zed gu inea pigs by 
a modification of the technique described by 
Landsteiner and Chase (48). Passive transfer was 
successful in three out of five expe riments (49) . 
The procedure involved the collection of mononu -
clear peritoneal exudate cells from guinea pigs 
with active photoallergic contact sensiti zation to 
TCSA. T hese were then injected intraperitoneally 
in to non-sensitive gu in ea pigs. T he inj ected 
gu inea pigs, when cha llenged 24 hours later, re-
acted to the combination of T CSA and light, 
while TCSA a lone or light a lone evoked no re-
sponse. 
In Vitro Tests. Additiona l experimenta l ev i-
dence in support of a delayed hypersen itivity 
mechanism included the in vitro demonstration 
by Jung (50) of lymphocyte transformation of 
ce lls from patients sensitive to Jadi t (buclosam-
ide). T hi s could be achieved on ly with a ligh t-
induced buclosamide-a lbumin complex, but not 
with buclosamide a lone. These findings have re -
ceived further support from in. vitro tests of 
Herman and Sams (51). They investigated the 
problem of carrier specificity in TCSA photoal -
lergy, using the macrophage migration inhibition 
technic. T he migration in tissue cu lture of sensi-
tized cells from guinea pigs contact photoa llergic 
to TCSA was 90 percent inhibited by an in. vitro 
prepared TCSA-albumin conjugate, as compared 
to 17 percent inhibition with TCSA a lone and 20 
percent inhibition with a lbumin a lone. These 
findings suggest an important role for the protein 
carrier in contact photoal lergy. 
T hu the proof of an a ll ergic mechanism in 
contact photoallergy rests on extensive clinica l 
eviden ce character istic of an allergic reaction ; 
experimenta l induction in human volunteers; 
experimental induction in gu inea pigs; passive 
transfer with mononuclear ce ll s in guinea pigs; 
y 
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FIG. 7. Hypothesis of mechanisms of allergic contact 
and a ll ergic photocontact dermatitis. 
334 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
and in vitro findings with the lymphocyte t rans-
formation and macrophage migration inhibition 
techniques (Table VI). 
Factors Influenc ing Photoallergic Reactions . 
Among the factors which influence the occurrence 
of photoallergic contact sensitization and of pho-
toa llergic contact reactions are the condit ions 
prevailing in the skin at the particular site and at 
the particular time. These include 1) the quant ity 
nnd location of photosens itizer present in or on . 
the skin; 2) the capacity of the photosensiti zer to 
penetrate into the skin; 3) the pH, enzymes (such 
as hydrolytic peptidases and catalases) and solu-
bility conditions at the site of exposure; 4) the 
quantity of activating radiation to which the skin 
is exposed; 5) the capacity of the wavelengths 
which activate the photosensitizer to penet rate 
the skin; 6) the ambient temperatu re and hu-
midity; 7) the thickness of the horny layer; 8) the 
degree of melanin pigmen tation; 9) the immuno-
logic state of the affected person. 
With respect to the activating rad iat ion, it 
must be remembered that the stratum corneum 
permits more long than short ul traviolet wave-
lengths to pass through . In addition, the vast 
. majority of solar radiation in the ultraviolet range 
is composed of wavelengths greater than 320 nm. 
Thus, the prickle cell layers are reached by rela-
tively little short ultraviolet light, in contrast to 
long ultraviolet and visi ble light; and the dermis 
is affected in a similar manner. 
One can summarize t he cl inical and experi-
mental findings to date by stating that contact 
photoallergy i a fo rm of cell mediated hypersen-
sitivity which , except for t he requirement of ex-
posure to light, in all other respects corresponds 
immunologically and cl ini cally to ordinary con-
tact allergy. 
It is important to stress several fea tures of con-
tact photoallergy whi ch at this time remain unre-
solved and which probably are going to be the 
subject of intensive investigation in the years to 
come. 
Persistent Light Reactivity. The most impor-
tant of these, from the practical viewpoint, is the 
problem of persistence of light reactivi ty. In the 
Ia ge majority of patien ts with contact photoal-
lergy the eru ption clears wi thin a few days or 
weeks after the photoallergen and sunlight have 
been avoided. There is ev idence, however, that 
their photoa llergic contact sensitization persists 
TABLE VI 
Experimental ev idence associating halogenated 
salicylanilide photosensitivity with delayed 
hypersensitivity 
Passive transfer with lymphocytes in guinea pigs 
Induction in man 
Induction in guinea pigs 
Macrophage inhibition test 
Lymphor.yte stimulation test 
for many years and that they remain free from 
further eruptions because they succeed in 
avoiding the photoallergen. Crow, Wilkinson and 
Osmundsen (52) in 1969 showed that many pa-
t ients who had become contact photoallergic to 
TCSA and related compounds, in 1961 still were 
sensitive in 1969. It was noteworthy t hat patients 
who had- been photopatch tested in 1967, showed 
more contact allergic reactions to related com-
pounds than patients who had not been retested 
during t he interven ing eight years . However, in 
close to one-third of a selected group of 72 pa-
tients with photoallergy to halogenated salicylan-
ilides seen in our department, t he cl inical reac-
tivity persisted for many months or years, despite 
avoidance of exposure to the photoallergen when 
these individuals were exposed to light. T his phe-
nomenon has been recognized at least since 1955 
when Sidi (53) reported it in Phenergan photoal~ 
lergy. Wiskemann and Wulf (54) called attention 
to it in chlorpromazine photoallergy. J illson a nd 
Baughman (38) coined the term " persistent light 
reactor" for the unfortunate patients affected by 
this serious disease. 
These individuals, for a ll practica l purposes, 
become disabled because they can expose t hem-
selves neither t o sunlight nor t o ordinary day-
light, and often react to light emitted from arti fi-
cial sources. An important and, at present, most 
puzzling feature, is the fact that their photose si-
t ivity is not limited to the wavelengths t o which 
the photoallergen originally had sensitized them 
but includes a broad spectral band ranging fro 1~ 
visible light through the sunburn range. Thus, 
persistent light reactors regularly show a patho-
logically abnormal reaction t o wavelengths 
shorter t han 320 nm, the so-called "sunburn 
range". It should be noted that similar to others 
(44) we have observed that the histopathology of 
this reaction is different from that described as 
characteristic of sunburn (55). 
Consequently, there are two extraordi nary fea-
tures which d ifferentiate persistent li ght react iv-
ity from t ransient photoallergic sensitivi ty . The 
first is that the light sensitivity persis1s for months 
or years, in the absence of continued exposure to 
the photoallergen, and the second is that there is 
a broad spectrum of light reactivity including a 
lowered erythema threshold. 
In an attempt to investigate the poosible role of 
a metabolic or other systemic anomaly in the 
pathogenesis of persistent light reactivity, a series 
of persisten t light reactors including caucas ians, 
negroes and orientals, has been stud ied by us. To 
date, no consistent abnormalities have been dem-
onstrated. The hepatic, renal and cardiac func-
tions of t hese patients have been found to be 
normal. Specific tests for uropor hyrin, copropor-
phyrin and protoporphyrins and tests for antinu-
clear antibodies all have shown normal results. 
T here is no greater than average incid ence of 
atopy. T he one consistent fi ding has been the 
preponderance of males in the 5th, 6th and 7th 
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d ecades. A similar age and sex preponderance has 
a lso been noted by us and others (56, 57, 42) 
a m ong transient light reactors. 
H ow can one ex pl a in pe rs iste nt light 
reac tivi ty? In 1964 we (58) suggested that t he sen-
s i t ivity in these individua ls is perha ps directed 
p rincipa lly aga inst the carri er pa rt of t he pho-
toantigen, ra ther tha n against the ha pteni c pa rt. 
T his s till rema ins a plausible pathogenetic mech-
a nism . According to this hypothes is the patien t at 
first becomes sensit i.zed aga inst t he complete 
photoant igen, consisting of the photoha pte n and 
t h e ca rri er. A state of persistent li ght reactivity 
w o uld a rise when the complete an t igen, con-
s is ting of hap ten and carri er, is no longer required 
for elucita tion of the reaction; rather, the ca rrier 
p a rt of the photoa ntige nic molecul e a lone now 
su ffices to eli cit the all ergic reaction. T he carrier 
whi ch might be a protein , nucleoprotein, ribonu-
cle ic ac id or polysaccharid e, could be formed or 
r e l eased upon exposure to sunlight or could be a 
substance a lready present in the skin at the t ime 
of exposure to radian t energy. 
Willi s and Kligman (44) proposed what they 
called a "s imple" explanation: photosensitivi ty 
p ers ists beca use the a ll ergen itse lf pers ists in t he 
skin over a protracted period of t ime. They were 
able to demonstrate the presence of a 11uorescent 
m ateria l in t he skin months after t he last expo-
sure ·to T CSA. They concluded that the a ll ergen 
must pe rsist in the dermis s in ce the epidermis 
t urns over every 28 days. T he lowered erythema 
t h reshold , accord ing to their hypothes is, is not a 
s unburn reaction at a ll , but is a react ion to long 
wave ul trav iolet li gh t that can be expla ined by 
t race a moun ts of longe r wave ul trav iolet radia tion 
e mi tted by a rtifi cial li ght sources des igned to 
e mi t 280- 310 nm radia ti on. In highly sensit ive 
subjects, these t race amoun ts would be suffi cient 
to e li cit a photoa ll ergic reaction. 
This explanation is not sat isfactory, s in ce our 
p e rsistent li ght reactors (49) and those of others 
(59, 60) do not react to long wave ul t ravi olet ligh t 
in t he glutea l area, bu t have a lowered minimal 
ery thema threshold to 280- 310 radiat ion in this 
area. Furthermore, t here is experimenta l ev idence 
su ggest ing that a state rese mbling pers isten t li ght 
reactivity ca n be induced in guinea pigs (43). 
Actinic Reticuloid. 
In "1969, Ive, Magnus, Warin a nd Wilson J ones 
(61) described a ser ies of 10 elderly ma les wi th 
pers isten t photosens it ivity. They had ecze ma tous 
changes in exposed a reas, sp reading to other pa rts 
of t h e body and leading to erythroderma. So me of 
the clini ca l a nd hi sto logic changes were sugges-
tive of lymphoma. T hey call ed thi s "actinic retic-
uloid " a chronic de rmatos is assoc iated with se-
vere ; hotosensiti vity and histo logic rese mblance 
to lym phoma. In 1970 J ensen a nd S neddon (62) 
descr ibed a pa tient who had had this di sease for 
n ine years and who now showed frank ret iculos is. 
It has not been poss ible for these authors to 
carry out phototests in most of these patien ts 
because of their wides pread s kin involve ment. 
T herefore one cann ot say whether t hey sta rted 
out as persisten t ligh t reactors. However, t here 
a re suffi cien t cl inica l and photobiologic parallels 
between actini c reticuloid and persistent li ght 
reactivi ty to at least arouse the suspicion that the 
former could be a late phase of the latter. 
F or t he t ime be ing one must assume that ra-
di an t energy plays two importa n t roles in pho-
toa llergic contact sensit ization: 1) it chemica lly 
a lters the a llergen, leading to the formation of the 
photoha pten through photooxica tion (e .g., forma-
t ion of parahydroxyla minobenzene sulfona mide in 
sulfanila mide photoa ll ergy) or through homolytic 
cleavage (e. g., of a ca rbon-ha logen bond and fo r-
mation of a ha logen-free radi ca l and a sa li cylan-
ilide-free radi cal in T CSA photoa llergy) or pe r-
haps t hrough still other mechanis ms; and 2) it 
fac ili tates conjugation of the photohapten wi th 
the carri er molecule, recombination a nd dimeri -
zation. The role of radiant energy in t he coupling 
of ha pten and carrier has been amply demon-
strated [Sulse r (62), Coxon, Jenkins and Welt i 
(47) , Harber and Baer (19), Jung et a! (50) and 
Herman and Sa ms (51)]. 
Con tact A Llergy us. Photocontact A llergy 
When a substance causes bDth a contact a l-
lergic reaction and a photoa llergic contact reac-
t ion in the sa me patient, a re the contact photo-
hapten a nd the contact ha pten the sa me? T here 
a re reasons to doub t t his very much. It a ppears 
possible that the contact photohapte n and the 
contact ha pten are the sa me in some instances, 
but that they are di fferent in other instances. 
T hey might be the sa me, for exa mple, in reac-
t ions where the photohapten is produced by one 
mechani sm, (e.g., photooxidation) and t hey might 
not be iden t ica l when the photohapten is pro-
duced by another mecha nis m (e .g. , free radica l 
formation). We have already given the reasons 
wh y they are likely to be diffe rent in TCSA pho-
toa ll ergy. If they were indeed a lways iden t ica l, 
then one should be a ble to elicit a positive ordi -
na ry contact allergic reaction in every patien t and 
animal with a contact photoa llergy, as long as one 
ca n bring about suffi cien t metaboli c activation 
before a pplicat ion of t he photosensit izer (43). 
One can summa ri ze the present state of contact 
photoa ll ergy as follows: knowledge of the clinica l 
di agnos is, diagnostic test procedure , and basic 
immunology is at a bout the same leve l as knowl-
ed ge of oridina ry contact all ergy. Among the 
impor ta n t proble ms in contact photoa llergy 
whi ch demand intensive investigation in the 
immediate fu ture a re 1) the nature of persistent 
ligh t reactivity in photoa ll ergic ind ividua ls and, 
in part icular, the eventual fate (lymphoma?) of 
some persons affected by t his state; and 2) the 
relationshi p between contact photoa llergy and 
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contact a llergy in individua ls in whom both co-
ex ist. 
Drug-induced Porphyria 
P hotosensit ivi ty assoc iated with high exc retion 
of porphyrins was probably first recogni zed by 
Schul tz (64) a nd Baumstark (65) in 1874. S ince 
tha t t ime, recognition of a variety of clinical fea -
tures, in combination with numerous adva nces in 
t he chemistry of tetrapyrroles of porphyrins, have 
led to the recognition of at least 14 types of por-
phyria (66) . Of prime interest as a mecha nism 
involving drug- induced photosens itiv ity is por-
ph yria cutanea tarda, described by Waldenstrom 
in 1937 (67) , a nd now often referred to as acquired 
hepati c porphyria. This condition , is cha racter-
ized by photosensitivity and a hi gh urinary exc re-
tion of uroporphyrin . Usin g monochromati c li ght, 
studies by Magnus (68) and others (69) has shown 
the action s pectrum to closely correspond to the 
a bsorption spectrum pea k of porphyrin at 405 
nm . Porphyrin s have been well -known to be pho-
tosensit izers in man since the class ica l studies of 
Meye r Betz with hematoporphyrin in 1913 (70) . 
T herefore, one can consider t he photosens itivi ty 
which occurs in porphyria cuta nea tarda an ex-
a mple of a photox ic reaction wherein t he host 
manufactures h is own photosens itizer. Although 
m a ny cases of porphyria cuta nea tarda a re known 
to occur in a lcoholi cs (71, 72), no exogenous age n t 
ca n be incriminated in many other patien ts. It 
now · a ppears that th e clinical features of por-
phyria cu tanea tard a may be related etiolog ica lly 
to multiple factors, including genetic (73, 74) , 
hormona l (75, 76, 77) and drugs (78, 79). 
T he s pecifi c role of dru gs a nd hormones in por-
phyria has been presented by Granick and Urata 
(80) in a unify ing hypothesis concernin g the regu-
lation of heme synthesis. Th is hypothesis has 
been. confirmed in man in acute intermi tten t 
prophyria by Tchudy et al . (81) and may have rel-
evance in porphyria cutanea tarda as well. G ran -
ick's studies indicated that porphyrin syn thes is is 
controll ed by a rate limiting mitochondrial en -
zy me, d elta a mino levul enic acid (ALA) synthe-
tase, which is synthetized in increased concentra -
tion under the influence of certa in drugs and 
hormones (82). A strong correlat ion was noted 
between porphyrinogenic activ ity of various 
agents in chi ck embryo hepatic tissue cul t ures to 
whi ch various drugs (83) were added (Tab le VII) 
and observations regarding t he induction of por-
phyria in man (Table VIII (84)). T he sali ent fea-
ture of Gran ick's hypothes is (Fig. 8) is that por-
ph yrin synthesis is contro ll ed by a repress ion ef-
fec t of its end product, the porphyrin , heme (85). 
T hi s porphyrin acts by combin ing with a n apore-
pressor that ca n inhibit the ope rator gene (Op) 
which in turn cont rols the structura l gene (SG) 
respons ible for ALA synthetase sy nt hesis . The 
structura l ge ne exerts its influence through a 
messenger RNA that resul ts in mitochondrial 
synthesis of ALA synthetase. Drugs and hormones 
could ac t by combining with or blocking th e re-
pressor s ite or its product whi ch is norma ll y u t i-
lized by heme to "turn off" gen e activity. Thus 
the " unres trained " gene (SG) would man ufacture 
in creased messenge r RNA for mitoc;hond ri a l syn -
thesis of the en zyme ALA synthetase. As a conse-
quence increased porphyrinogenesis would occur. 
This observation, though confirmed in experi-
mental models, has been d ifficult to demonstrate 
in man . In addi t ion, the re are alternative hy-
potheses regard ing increased porphy rin synthes is . 
Labbe et a l (86) have suggested that drugs may 
exe rt their influence by a lte rin g the e lectron 
t ra ns port system of hepatic ce lls . This cou ld re-
TABLE VD 
Selected examples of porphyrogenic activity of drugs 
tes ted in chich embryo liver cell cultures* 
PhormucologicH I uction 'ompounds t c~ t cd 











Other chemi ca l agents 
• (Ref. 84) 
Hydantoins 
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Phenylbutazone 
Probenec id 
Chlora mph eni col 
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Drugs and other agents associated with the onset or 
aggravation of porphyria cu.tanea tarda in. man 
Ethyl alcohol 
Hexachlorobenzene 
Di - and t ri chlorophenols 
Stilbesterol a nd other estrogens 
Chloroquin 
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FIG. 8. E xa mple of a schema for cont rol of porphyrin 
syn thes is by a repressor action on a opera tor gene (85). 
O peron theory suggests that drugs may in te rfere with 
t h e norma l represso r action ini t iated by a high concen-
t ra tion of certa in prophyrins (Heme). 
s ult in increased format ion of succinate and suc-
c inyl-CoA and lead to the manufacture of in -
c r eased porphyrins. Gadjos (87) et a! proposed 
t h a t it may be t he lowering of hepatic ATP by 
drugs which resul ts in an increased syn thes is of 
p o rphy rins. It is a lso poss ibl e t hat hepa ti c 
ha mage per se, as noted in post-nec rotic hepatic 
c irrhos is by Levere (88), can result in increased 
ALA sy nthetase activity and res ul ta n t porphyrin 
synthesis. 
That drugs a re clinica lly capable of inducing 
porphyri a cuta nea ta rda in man was drama t ica lly 
d e monst rated in 1956 when thousands of individ -
ua ls developed porphyria in Turkey (89, 90). Epi -
d e mi olog ic s tudies revealed a dive rse genet ic 
b a ckground of the a ffected individua ls, but they 
all had ingested whea t to which t he an t ifunga l 
agent, hexac hlorobenzene, had been added . Sub-
sequent s tudies revea led that hexachlorobenzene 
can read ily induce porphyri a in experimenta l 
a nimals such as ·rats (91) and ra bbits (92). An in -
crease in ALA synthetase activi ty and porphyrin 
synthes is in chick e mbryo liver t issue cul ture was 
a lso shown to occur when hexachlorobenzene was 
added (83). Exposure to the chemica lly related di -
a nd trini t roph enols have a lso been associated 
with the developm ent of porphyria in 23 in -
dustria l workers in a chemica l factory loca ted in 
New J ersey (93). 
Induct ion, as well as aggravation of porphyri a 
has been noted in patients receiving est rogen and 
stilbeste rol thera py (94, 95) . T here has a lso been a 
m a rked increase inporph yria cutanea tarda in 
wo men rece iving contrace pt ive hormona l therapy 
(75, 76) . T hese estrogen co mpounds a re a lso 
kn own enzyme induce rs of ALA synthetase in 
exp erim enta l models and have been postulated to 
b lock or compete fo r t he repressor s ite norma lly 
res ponsive to heme (85). It must be s tressed t hat 
thi s hypothesis relating to t he rate limi t ing ac -
t ivity of delta a minolevulenic ac id synthetase 
awaits confirmation in porphyria cuta nea tarda . 
W h ateve r the mecha ni sm is ul t ima tely found to 
be, it ca n be an t icipated t hat with t he in t roduc-
t ion of new syn thetic drugs, including hormones 
and hepatotox ic chemicals, syn thes is by t he host 
of his own photosensit izers will con t inue to pose a 
poten t ia l hea lt h hazard . 
Drug-induced Lupus Ery thematosus 
Syste mi c lupus ery th ematosus (S LE) , was 
probably firs t recogni zed as a discrete ent ity by 
Batema n in 1817 and has been well reviewed his-
tori ca lly by Ormsby and Montgo mery (96). Since 
1948 (97) when the Ha rgrave cell was in t roduced 
as a diagnostic a id , extensive laboratory studies of 
SLE in man a nd experimenta l anima ls have be-
come feas ible. Still , t he et iology of SLE remains 
unknown, a lthough SLE has been attribu ted to 
bacteria l (98), vira l (99) , lysosoma l (100) , immu-
nologic (101), connective t issue (102) , hormona l 
(103), genet ic (104), psychic (105) and other fac-
tors . Any discussion of the role of drugs in the 
induction of photosensit ivity in SLE is compli -
cated by the fact t hat exposure to li ght , without 
exposure to a drug, and exposure to a drug, 
wi thout exposure to sunli ght are a lso known to 
induce clinica l exacerbations of SLE. Moreover, 
it cannot be ove remphasized t hat there is extreme 
difficul ty in se pa rating cause from effect in a dis-
ease of unknown etiology. For at least the past 20 
yea rs (1 06, 107, 108), SLE has been reported to 
have occurred as a consequence of exposure to 
drugs. Drugs have been implicated in 3- 12% of 
SLE patients t udied (1 09). Sunlight a lone as a 
precipi tating or agg ravating factor of this disease 
was repo rted by Rasch in 1926 (110) and has been 
noted to play a role in as high as 33% of SLE pa-
tien ts studied (111). 
An in tri gu ing recen t ly proposed concept is that 
a photoreaction between the drug and the host 
t issue or between light and a " drug-tissue uni t" 
can produce immunogenic compounds t hat in i-
tiate or exacerbate SLE. 
Role of Drugs A lone. Reports by Gold et al. 
(106), Walsh et al. (107) and Miescher et al. (108) 
indicated that sulfonamides, penicillin , ant ihy-
pertensive agents a nd hydralaz ine are im pli cated 
in the pathogen esis of SLE. Ladd, in 1962, clearly 
delineated the proca ina mide- induced SLE syn-
drome (112). T he li st of drugs which can a lso in -
duce or exacerbate SLE has ra pidly expanded 
and at presen t in cludes the agents listed in Table 
IX (113, 114). T hese age nts have no molecular 
s imilarit ies nor pharmacologic action in common. 
However, egovia has suggested that they may be 
divided in to two groups: One group of drugs acts 
via a n immunolog ic mechani s m a nd a nother 
group of drugs induces SLE because of its pa rt ic-
ula r pha rmacologic properties (ll5). One of his 
immunologic observat ions, t hat meri ts fur t her 
study, is that ant ibodies to soluble nucleoprotein 
a ltered by hydrazide occur in approx imately 80% 
of pat ien ts with SLE rece iving therapy with INH, 
whereas in the cont rol group of patien ts with tu-
berculosis who were not t reated with INH, ant i-
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bodi es to nucl eoprote in a lone were found in a 
much small er n umbe r. 
Role of Light A lone. ll has been estimated (115) 
t hat while cuta neous manifestat ions occur in a p-
proximate ly 80% of SLE pa ti ents, cutaneous reac-
t ions to light occur in onl y 30%. The res ponse to 
li ght by some has been cons idered a non-spec ifi c 
iso morphi c ph eno menon (116). This could be 
m ediated via a lysoso mal mecha nis m ( llO) . 
Another possib ility is t hat li ght (280- 315 nm). 
induces nuclea r a lte rations which in turn res ul t in 
t he formation of immunogeni c a lte red nuclea r 
mate ria l. Tan (117) has d emonstrated this in ex-
pe rimen ta l a ni ma ls. In this connection it should 
be noted that Leste r (118) has reported a co rrlea -
tio n between photosens it ivity and the presence of 
an ti nuclear a nt ibodies in ma n. Thus, it is poss ible 
that li ght, wit hou t t he presence of a drug, could 
induce a n immunologic response of the auto i m-
mune type via altered nucl ea r mate ria l. 
Role of Drugs plus Light . B lo mgren a nd 
Va ugha n (119) have recent ly demonstra ted a pos-
s ibl e mod el for drug-i nduced photose ns it iv ity 
react ions in SLE. T hey ut ili zed a photoox idized 
p rep'a ration of proca inamide linked to DNA at 
the gua ni ne res idue. The immunogeni c potentia l 
of this mate ria l in rabbi ts was compared with 
that of photoox idi zed DNA a lone, a nd wi t h non-
photoox idized DNA. Whil e a ll three of these ma-
te ria ls ha d immunogenic potenti a l, the potentia l 
of the photo-ind uced proca ina mide-D NA compl ex 
was greatest, fo ll owed by photoox idi zed D NA a nd 
non-photoox idi zed D N A. It is obvious that the 
role of drug plus li ght in t he inducti on a nd exac-
erbation of SLE requires much fur t her study. 
Clea rl y t here are a rg1,1ments in support of a ll 
three major ex planat ions, ent irely a part from the 
other p rev ious ly noted etiolog ic factors which 
have bee n proposed for SLE. It is our fee ling that 
photosensitivity in SLE may have severa l pa tll o-
genetic mechan isms. P rominent a mong these is 
an im munolog ic reaction based on the photo-
chem ica l formation of an a nt igen (photoant ige n) , 
consistin g of nuclea r materia l coupl ed to a drug 
or pa rt of a d rug mo lecule. T he role of I ight in the 
production of this photoan t igen would be to pho-
TABLE lX 
Drugs and hormones associated with systemic lupus 
erythematosus 
Penici ll in 
Su lfonam ides 
Tetracycline 
Streptomycin 













Methylphenyl ethylhydantoi n 
Hydralazine 
Diphenylhydantoin 
tochemica lly a lter t he drug and/or facili tate its 
binding to DN A. l t is not inconce iva ble t ha t t he 
nuclea r co mponen t of t he drug photoa n t ige n 
could be nuclea r mate ria l a lready a lte red by li ght 
a lone. Furt hermore, the poss ibility 0 f cross- reac-
tions a mong a structura lly close ly s imila r drug 
photoantigen a nd a D NA photoan t igen, not cou-
pled to a drug or d erivative of a drug, must be 
cons idered. 
Drug-induced Pel/agar-like Eruptions 
P ellag ra, a term coined by Fra poli in 1771 to 
refer to ce rta in pat ients wi t h " rough skin " was 
firs t reco~ni zed as a distinct morphologic ent ity 
by Casa l 111 1735 (1 20) . It was soon rea li zed t hat 
pellagra was a systemic disease wi t h ma rked pho-
tosens it ivity. The numerous theories adva nced 
during the next two centuri es concernin g the 
etiology of this condition which has affected mil -
li ons of individua ls, have recently been compre-
hens ively reviewed (121) . Following Goldberge r 's 
mge111ous epid emiologic studi es in 1913, it was 
de ~n.ite l y est a blished that pe ll agra was a dieta ry 
de!Iciency di seas.e 0.2~). Th~ re is. presen t ly strong 
ev idence that ni cotmic ac id (niac in) and /or its 
precurso r, the essentia l a mino ac id t ry pto pha n 
a re the factors wh ich a re defi cient in t hi s di s~ 
order. lt is now a lso known t hat ni ac in , in the 
form of ni cotina mid e, is necessary for the syn -
t hes is of diphos phopyridine nucl eotide (N ADP) 
a nd t riphos ph opy ridin e nucl eot id e (NADPH). 
These age nts a re vita l in media tin g hydrogen 
t ransport in t he ox idative- reductive reacti ons of 
norma l ce llula r metaboli sm . The cuta neous le-
s ions or pellagra a re prec ipita ted by s kin da mage 
e.g. sunli ght irradi at ion of the "exposed" ski ~ 
areas a n~ maceration a nd fri ction in in te rt rigi-
nous reg iOns such as the groins. A possible b io-
chemica l ex pla nation for these profound effects of 
relat ive ly minor da mage to the skin may be the 
!:act t hat both N ADP and N ADPH a re obligatory 
lor c.e llula r ene.rgy t ran~ fe r reactions. One mi ght 
predi ct tha t t issues wi t h high energy require -
ments such as the bra in , or wi t h a ra pid ce ll t urn -
o~er time such as mucosa and skin , would be t he 
Sites of major metaboli c dera nge ment if there 
we re impa ired ce llul a r energy t ra nsfe r. Indeed it 
is these 3 major regions which class ica lly show the 
clin ica l abnormaliti es of pellagra, namely, d emen-
t ia, diar rhea and d ermat itis. It is tempt ing to 
s peculate t ha t t he cuta neous mecha ni s m is 
simply t ha t t he skin is unab le to repa ir the epi -
d e rm a l da mage fo llowin g 300 nm ra diat ion 
wit hout suffi cient NA DP a nd NADPH. Ex peri -
menta l proof for this hypothes is, however, is 
lac kin g to date . 
Drugs which act to inhibi t try ptophan or nico-
t inic ac id metabolis m would a lso be predi ctable 
induce rs of pellagra a nd photosensiti vity. T his 
s ituation has indeed been obse rved with t he an t i-
tubercul ous drug isoni az ide (IN H). P hotosensi -
t ivity a nd pellagra -like erupt ions have been re-
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C- NH2 o-~ og-NH-NH, 
isoniazid i INH) 
N 
nicotinamide 
FIG. 9. Structural simila ri t ies between nicotina mide 
a nd isoniazid suggest tha t INH may inhibi t synthesis of 
DPN by a co mpetitive inhibi tion mechanism. 
ported by M cConne ll (123), H arri son , (124), a nd 
oth ers ( 125, 126) . As t he che mi ca l structure of 
INH resembles t hat of ni cotina mide (F ig. 9) , a 
competitive inhibition reaction by INH is a plau -
s ibl e hy poth esis to account for drug- induced pho-
tosens iti vity in a s kin con ta ining low leve ls of 
NADP a nd NADPH. The administration of 6-
mercaptopurine, whi ch inhibi ts NADP syn thes is 
(127), a nd of 5- lluorourac il , have both been asso-
c ia ted with pell agra- like erupti ons (1 28). 5-fluo-
rourac il ca n inhibi t t he enzy matic con version of 
try ptopha n to ni ac in a nd in t his ma nner may af-
fect t he s kin by inhibi t in g nucleotide repair. 
Of in te rest, t hough unrelated to drugs, is t he 
fact t hat photosens itiv ity has a lso been noted in 
the genetic co nd ition, Ha rt nup 's disease, a nd in 
ca rci noid syndrome. The pathoge nes is of H a rt-
I1Up 's disease re mains unknown ; howe\·er, it has 
been noted tha t pa ti en ts with tha t d isease im-
p rove foll owing ni cotin ic ac id t hera py (129). A 
poss ibl e m echa nism is t hat pa t ients with Hart-
nup 's disease have a n in testina l defect in trypto-
phan absorpti on as well as a rena l d efect in reab-
sorp t ion of a min o acids, both of whi ch could lead 
to ni ac in defi c iency. In t he ca rc inoid syndrom e 
the excretion of 5-hydroxy indole acetic ac id in 
a bnorma lly la rge a m oun ts ha been shown to re-
s ult in a re lat ive d efi c iency of its precursor, t ry p -
tophan . T hus this condi t ion can a lso eventuate in 
a niac in de fi c ie ncy (130). Future experimen ta l 
stud ies may show m ore t ha n t he fragmentary re-
lationship that now exists between t he pellagra-
like p hotose nsiti vity erupt ions ·een with d rug 
t hera py, ca rc inoid syndrome a nd artnu p's d is-
ease. 
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